Oye Olukotun, MD, MPH,FACC, Acting Chairman
Oye Olukotun, MD, MPH, FACC, is a Board Certified Cardiologist who has been instrumental in the submission of more than fourteen New Drug Applications, Premarket Authorization Applications, and 510k Applications in 30 years he has spent in pharmaceutical and medical device industries. Previously, he was the co-founder of VIA Pharmaceuticals and served as the Chief Medical Officer. Before joining VIA, Dr. Olukotun founded CR Strategies, LLC, a clinical research and development consulting firm in Princeton, NJ, and served as its Chief Executive Officer. He also was Chief Medical Officer of Esperion Therapeutics, Inc., a cardiovascular drug development company, until its acquisition by Pfizer. From 1996 to 2000, Dr. Olukotun was Vice President of Medical and Regulatory Affairs and Chief Medical Officer of Mallinckrodt, Inc. Prior to joining Mallinckrodt, Dr. Olukotun spent fourteen years at Bristol-Myers Squibb Company, where he served as Vice President of two divisions focused on cardiovascular research. Dr. Olukotun received his MD degree from Albert Einstein College of Medicine and obtained a MPH degree from Harvard University School of Public Health. Throughout his career, he has published more than forty articles in peer-reviewed scientific journals. He is a Fellow of the American College of Cardiology as well as the American Heart Association. He is also currently a member of the Boards of Directors of BioClinica, Icagen, Milestone Pharma, and SemBioSys.
Renay A. Ebelle, PhD, Vice-Chairman
Renay Ebelle, PhD, is a seasoned industry leader with combined business and technical experience and over 18 years of experience in the pharmaceuticals, biologics and medical device industries.
Previously Renay was the Vice President at Renalex Group LLC, a key player in the life science industry providing regulatory, and market entry strategy, where he led global Regulatory and clinical development programs. Prior to that, he was with Mela Sciences Inc. a leader in melanoma diagnostic, leading strategies for the regulatory, quality and clinical divisions which he helped build. At Mela Sciences, his efforts led to the launch of the first-in-kind melanoma medical diagnostic device “MelaFind” for melanoma detection, in the US and Europe. Prior to Mela, Renay worked at top fortune 500 companies including Johnson and Johnson, Watson Pharmaceuticals, and TyRx Pharma, where he held diverse senior management positions.
Renay graduated from the University of Ivory Coast in Abidjan with a Master of Sciences and a Doctorate in Biochemistry. He attended Columbia University where he received his PhD in cellular immunology. Renay holds a six sigma green belt for excellence from Lockheed Martin and is an MBA from Rutgers Business School with a focus on Pharmaceutical Management and finance. Renay is a co-author of several publications and patents
Previously Renay was the Vice President at Renalex Group LLC, a key player in the life science industry providing regulatory, and market entry strategy, where he led global Regulatory and clinical development programs. Prior to that, he was with Mela Sciences Inc. a leader in melanoma diagnostic, leading strategies for the regulatory, quality and clinical divisions which he helped build. At Mela Sciences, his efforts led to the launch of the first-in-kind melanoma medical diagnostic device “MelaFind” for melanoma detection, in the US and Europe. Prior to Mela, Renay worked at top fortune 500 companies including Johnson and Johnson, Watson Pharmaceuticals, and TyRx Pharma, where he held diverse senior management positions.
Renay graduated from the University of Ivory Coast in Abidjan with a Master of Sciences and a Doctorate in Biochemistry. He attended Columbia University where he received his PhD in cellular immunology. Renay holds a six sigma green belt for excellence from Lockheed Martin and is an MBA from Rutgers Business School with a focus on Pharmaceutical Management and finance. Renay is a co-author of several publications and patents